5PSQ-010 Efficacy and safety of agalsidase alfa in fabry disease

BACKGROUND: Fabry disease is included within the lipid deposition diseases that occur due to mutations in the gene that encodes the α-galactosidase enzyme. As a consequence, a fatty substance, globotriosilceramide (GL-3), is responsible for the illness of different organs such as the heart, eyes or...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur J Hosp Pharm
Главные авторы: Rosa, V González, Gil, E Atienza, Torres, MI Sierra, Rascón, M Zaragoza, Alonso, M Pajares
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Group 2018
Предметы:
Section 5: Patient safety and quality assurance
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535223/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.364
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы